$SYRE
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Healthcare
Sector
Biotechnology
Industry
Jonathan D. Alspaugh
CEO
69
Employees
$73.52
Current Price
$48.63M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 7 | $2,214,398.00 | 30,833 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 7 | $2,214,398.00 | 30,833 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 11 | $8,166,448.43 | 110,833 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 25 | $15,729,781.59 | 216,666 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 30 | $17,237,669.91 | 247,124 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.